Aqilion today announces positive results from the ARIA-2 clinical study. The study evaluated the pharmacokinetic profile in healthy participants of a novel, water-dissolvable tablet formulation of ...

AQILION (publ) announces today that it has successfully completed the first clinical study in humans within the Regulus program. The Phase 1 ARIA-1 study was conducted to evaluate the safety, ...

Aqilion, a Swedish biopharma company developing therapies for diseases driven by chronic inflammation and dysregulated immune responses, has reported positive results from a pharmacokinetic study ...

Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Eosinophilic Esophagitis - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. This report offers a detailed examination of the ...